

Sending the Bears back into Hibernation with these 3 potential Short Squeeze NASDAQ Stocks

Sending the Bears back into Hibernation with these 3 potential Short Squeeze Stocks

CLINTON TOWNSHIP, MICHIGAN, UNITED STATES, March 19, 2024 /EINPresswire.com/ -- Sending the Bears back into Hibernation with these 3 potential Short Squeeze Stocks

What is a Short Squeeze:

A short squeeze is an unusual condition that triggers rapidly rising prices in a stock or other tradable security. It occurs when a security has a significant amount of short sellers, meaning lots of investors are betting on its price falling. The short squeeze begins when the price jumps higher unexpectedly and gains momentum as a significant measure of the short sellers deciding to cut losses and exit their positions.

The 3 Stocks we feel you should put on your watchlist ASAP that have all been sold Short are:

“

A short squeeze happens when many investors bet against a stock and its price shoots up instead as short sellers bail out to cut their losses”

Investopedia



GDHG, NRPX, and RENB

Golden Heaven Group Holdings Ltd. ([Nasdaq: GDHG](#)); New Amusement Park Attendance Record Set, Preceding Major Expansion into Indonesia with 30-50 New Park Openings, \$6 Million Dollar Share Repurchase Plan

Golden Heaven Group Holdings Ltd. (Nasdaq: GDHG) manages and operates six properties consisting of

amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the GDHG parks are easily accessible to an aggregate population of approximately 21 million people.

The GDHG parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities.

Currently Managing Six Properties Consisting of Amusement Parks, Water Parks, Gourmet Festivals, Circus Performances and High-Tech Facilities.

- Parks are Located in Geographically Diverse Markets Across the South of China and Collectively Offer Approximately 139 Rides & Attractions.
- Parks are Easily Accessible to an Aggregate Population of Approximately 21 Million People in China.
- Guest Visits During the 2024 Chinese Spring Festival Holiday Set New Company Attendance Record.
- Expanding Into Indonesia Market via Strategic Partnership with PT BESTAR JAYA.
- Authorized \$6,000,000 Share Repurchase Program for GDHG Common Stock.
- Utilizing Capital Market to Broaden Presence in the Amusement Park Industry.



NASDAQ: NRXP



NASDAQ: RENB

□ Enhancing Operational Efficiency and Refining Investment Strategies.


□ Increasing Investment in Technology to Elevate Visitor Experiences and Improve Overall Customer Satisfaction.

For more information on \$GDHG visit:
<https://axecapitalusa.com/gdhg/>

NRx Pharmaceuticals ([NASDAQ: NRXP](https://www.nasdaq.com/markets/nrxp)); Future Shipment of IV Ketamine to over 100 Pharmacies Nationwide; Trial Endpoint Reached for First Suicidal Bipolar Depression, Chronic Pain and PTSD Drug; Potential for up to \$330 Million in Payments and Royalties

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRXP has partnered with AlvoGen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has the potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for the development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.



\$RENB



NRx Pharmaceuticals, Inc.
1201 N Orange St., Suite 600
Wilmington, DE 19801
Phone: (484) 254-6134
<https://www.nrxpharma.com/>

Ticker (Exchange)	NRXP-NASDAQ
Recent Price (12/01/2023)	\$0.344
52-week Range	\$0.22 - 1.51
Shares Outstanding	81.9 mm
Market Capitalization	\$28.2 mm
Average 10-day volume	259,600
Insider Ownership ->5%	22.3%
Institutional Ownership	5%
EPS (Qtr. ended 09/30/2023)	(\$0.07)
Employees	10

NRx Pharmaceuticals, Inc. (NRXP-NASDAQ)
One-year Stock Chart



DCS-LURASIDONE INTERACTION



COMPANY DESCRIPTION

NRx Pharmaceuticals, Inc. ("NRx" or "the Company") is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders with high unmet medical needs. The Company's foundation product is NRX-101, a patented combination of two FDA-approved drugs—**D-cycloserine (DCS)**, an NMDA receptor modulator; and **lurasidone**, an atypical antipsychotic medication. The Company is assessing the use of NRX-101 in four different indications: suicidal **bipolar depression**, chronic pain, **post-traumatic stress disorder (PTSD)**, and **complicated urinary tract infections (UTI)**. Development of NMDA antagonists, such as DCS, as antidepressants has been limited by their potential **psychedelic** side effects. Furthermore, **serotonin**-targeted drugs like lurasidone have been limited by their own behavioral side effects, specifically **akathisia**. Professor Daniel Javitt (NRx Co-founder and Chair of its Scientific Advisory) made the simultaneous discovery that: (1) the psychedelic effects of NMDA antagonist drugs could be reversed by combining them with serotonin-targeted compounds; and (2) NMDA inhibitors, in turn, block the akathisia side effect normally associated with serotonin-targeted drugs. The previously undiscovered synergy between these two drug classes is the subject of 48 issued patents and 43 pending patents owned by or licensed to NRx Pharmaceuticals, and as such, is the medical and scientific basis for the Company's technology platform.

KEY POINTS

- NRx entered into a collaboration with AlvoGen Pharmaceuticals for the development and commercialization of NRX-101 in suicidal bipolar depression, with the potential for up to \$330 million in milestones and double-digit royalties.
- NRx is conducting a single Phase 2b/3 trial of NRX-101 for **Suicidal Treatment Resistant Bipolar Depression (S-TRBD)**, with topline clinical data readout expected by Q1 2024, potentially followed by an NDA application shortly thereafter.
- Under the AlvoGen agreement, a successful data readout and completion of a **Type B meeting** with the FDA would trigger a \$10 million payment to NRx, at which point, AlvoGen would be responsible for all future development and commercialization costs for this indication.
- NRX-101 is also being evaluated for the treatment of chronic pain as a non-addictive substitute for **opioid** products. The Company is planning to start a pharmacokinetic study following result readout of a 200-person U.S. Department of Defense-funded trial in treating chronic pain with DCS.
- NRx is assessing plans to create spinoff companies to complete development of NRX-100 (IV ketamine) for acute suicidality and NRX-101 for UTI, which would potentially provide investors with both capital appreciation and a royalty stream.
- As of September 30, 2023, NRx's cash and cash equivalent position was \$8.9 million.

\$NRXP Research Report

- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain, and PTSD.
- MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies.
- Study Maintained 95% Concordance Rate Between Study Sites and Central Raters on Primary Endpoint. No Unexpected Serious Adverse Events Reported.
- Positive Sata and FDA Comment Triggers next \$5 Million Payment from Partners Alvogen and Lotus and their Assumption of Development Costs with up to \$330 Million in Milestone Payments and a Royalty on Net Sales in the Mid-Teens.
- Completed Initial Manufacture of IV Infusion and Plans to File FDA New Drug Application for Acute Suicidality Upon Demonstration of 2-year Shelf Stability.
- Completing Enrollment for Phase 2b/3 Trial in Suicidal Treatment-Resistant Bipolar Depression in Cooperation with Lotus Pharmaceutical.
- Incorporation of HOPE Therapeutics Dedicated to NRX-100 (IV Ketamine) for Suicidal Depression to Patients.
- HOPE Therapeutics to be Initially Owned by NXRP and current NXRP Shareholders via a Planned Tax-Free Dividend.

For more information on \$NRXP visit: <https://www.nrxpharma.com/> and <https://axecapitalusa.com/nrxp/>

Renovaro Biosciences Inc. ([Nasdaq: RENB](https://www.nasdaq.com/markets/stocks/renb)); Breakthrough Testing with Nvidia AI Chips Emerging from Cyclomics Acquisition and GEDiCube; Early Cancer Detection

Renovaro Biosciences, Inc (Nasdaq: RENB) has developed advanced cell, gene, and immunotherapy platforms designed to renew the body's natural tumor-fighting capabilities against cancer and infectious diseases.

RENB is harnessing the power of genetic expression and gene therapy. The RENB AI platform finds correlations between genes and their expression. RENB gene therapy has the potential to teach the patient's immune system to recognize their cancer and destroy it. RENB will have the ability to inform and design clinical trials with insights from the deep learning of NVIDIA Partnered GEDiCube. RENB expects to make adjustments for their upcoming human clinical trials and test them in silicon.

- Developing Cell, Gene & Immunotherapy Platforms to Renew Natural Tumor-Fighting Capabilities Against Cancer and Infectious Diseases.
- Partnership with NVIDIA to Utilize Advanced Artificial Intelligence (AI) Chips.
- Proprietary AI Platform Aims to Commercial Products to Support Clinical, Research, and Pharmaceutical Organizations.
- RENB Will Acquire 75% of Cyclomics with 4th Generation Liquid Biopsy Genomics Platform “Omni-Omic” Blood Test Ready for AI Application.
- Cyclomics’ 4th generation liquid biopsy genomics platform is the first truly “Omni-Omic” blood test ready for AI application.
- Achieving in Pre-Clinical Studies what Dr. Anahid Jewett, a Top Oncological Immunology Scientist at UCLA Calls “The Holy Grail of Cancer Research.”
- Finalized Clinical Protocol and Identified Principal Investigator from the Department UCLA to Conduct First-In-Human Studies Projected for The End of 2024.

For more information on this Exciting NASDAQ Company: RENB

visit: <http://www.renovarobio.com> and <https://axecapitalusa.com/re nb/>

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details that were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$3,500.00 by a third party for the dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning

of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In light of these uncertainties, the forward-looking events referred to in this release might not occur.

SOURCE: CorporateAds.com

Hank

CAP Inc.

+1 586-801-9002

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/696925899>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.